More Ways to Get AURYXIA

Auryxia® (ferric citrate) tablets

Get your patients started with the AURYXIA Free Trial Program*

Enrolled clinically appropriate patients will receive a FREE supply† of AURYXIA sent directly to their home, along with helpful educational resources.

Enroll your patients today!

Scan the QR code to enroll or visit AURYXIAHCP.com/freetrial

Print and fax this enrollment form to 833-702-3436

- Once your request is processed, AURYXIA will be shipped directly to your patients

*For patients new to AURYXIA and who have not previously enrolled in the program. This free trial prescription is valid for one time only with no refills. There is no obligation to continue use of AURYXIA after the free trial. If AURYXIA is right for your patient, a new prescription is needed to continue treatment. Terms and conditions apply.

†Supplied in 1 bottle of 100-count 210 mg ferric iron tablets.

Alternatively, you may continue to order samples for clinically appropriate patients

- Contact your AURYXIA representative or visit AURYXIAHCP.com to request samples

Connect with your representative for more information

Please see full Important Safety Information on the following page and click here for full Prescribing Information, or go to AURYXIAHCP.com

Not actual size.

INDICATION

AURYXIA® (ferric citrate) is indicated for the control of serum phosphorus levels in adult patients with chronic kidney disease on dialysis

IMPORTANT SAFETY INFORMATION

CONTRAINDICATION

AURYXIA® (ferric citrate) is contraindicated in patients with iron overload syndromes, e.g., hemochromatosis

WARNINGS AND PRECAUTIONS

- **Iron Overload:** Increases in serum ferritin and transferrin saturation (TSAT) were observed in clinical trials with AURYXIA in patients with chronic kidney disease (CKD) on dialysis treated for hyperphosphatemia, which may lead to excessive elevations in iron stores. Assess iron parameters prior to initiating AURYXIA and monitor while on therapy. Patients receiving concomitant intravenous (IV) iron may require a reduction in dose or discontinuation of IV iron therapy
- **Risk of Overdosage in Children Due to Accidental Ingestion:** Accidental ingestion and resulting overdose of iron-containing products is a leading cause of fatal poisoning in children under 6 years of age. Advise patients of the risks to children and to keep AURYXIA out of the reach of children

ADVERSE REACTIONS

The most common adverse reactions reported with AURYXIA in clinical trials were:

- Diarrhea (21%), discolored feces (19%), nausea (11%), constipation (8%), vomiting (7%) and cough (6%)

SPECIFIC POPULATIONS

- **Pregnancy and Lactation:** There are no available data on AURYXIA use in pregnant women to inform a drug-associated risk of major birth defects and miscarriage. However, an overdose of iron in pregnant women may carry a risk for spontaneous abortion, gestational diabetes and fetal malformation. Data from rat studies have shown the transfer of iron into milk, hence, there is a possibility of infant exposure when AURYXIA is administered to a nursing woman

DRUG INTERACTIONS

When clinically significant drug interactions are expected, e.g., Ciprofloxacin or Doxycycline, separate timing of administration.

To report suspected adverse reactions, contact Akebia Therapeutics, Inc. at **1-844-445-3799**

Please see full Prescribing Information

Auryxia® (ferric citrate) tablets

Akebia® THERAPEUTICS